Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U1 small nuclear 57, pseudogene (RNU1-57P) is listed in human genome annotations as a pseudogene—specifically, a member of the non-coding small nuclear RNA U1 family, but without coding function[5]. Unlike canonical U1 snRNAs (such as RNU1-1), which are essential for accurate pre-mRNA splicing and transcriptome integrity, RNU1-57P does not produce a functional RNA and is not involved in splicing or transcriptional regulation[1][5]. Pseudogenes like RNU1-57P are remnants of genomic evolution and do not serve as direct molecular or therapeutic targets[5]. The entry is correctly abbreviated as RNU1-57P, matching the HGNC nomenclature[5]. Any reference to U1 snRNA biological functions pertains to active, non-pseudogene family members (e.g., RNU1-1), not RNU1-57P[1][5]. It is not a receptor, enzyme, transporter, or any other pharmacologically actionable target. There is no evidence of this locus being implicated in disease or targeted by drugs. All major databases, including GeneCards and HGNC, consistently classify RNU1-57P as a pseudogene with no known function, clinical relevance, or drug interactions[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 57, pseudogene (RNU1-57P).